<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28253">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01695616</url>
  </required_header>
  <id_info>
    <org_study_id>ACH-SNT-03(01/12)</org_study_id>
    <nct_id>NCT01695616</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Passiflora Incarnata and Isoflavona Combination in the Treatment of Climacteric Symptoms</brief_title>
  <acronym>Monalisa</acronym>
  <official_title>A Phase III, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Passiflora Incarnata and Isoflavona Combination in the Treatment of Climacteric Symptoms.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ache Laboratorios Farmaceuticos S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ache Laboratorios Farmaceuticos S.A.</source>
  <oversight_info>
    <authority>Brazil: Ethics Committee</authority>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of Passiflora incarnata and Isoflavone
      combination in relieving the symptoms associated with Climacteric Syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is known that Hormone Therapy is recommended postmenopausal women to reduce menopausal
      symptoms and prevent osteoporosis frames and cardiovascular disease. However, only 30 to 40%
      of women still using hormone therapy.

      One reason women do not continue or are reluctant to start Hormone Therapy is realizing that
      the prescription of hormones is not a natural situation. Therefore, there is an increased
      interest in the use and prescription of estrogen derived from plants, known as
      fitoestrogênios.

      The development of a drug containing two standardized extracts was focused on two main
      symptoms of menopause: hot flashes and anxiety. This product comes from a longing for the
      doctors themselves can respond more promptly to patients who reach menopause and who already
      has a framework for mild to moderate anxiety.

      Thus, to meet the woman who develops menopausal symptoms and that these two are highly
      prevalent during menopause, causing intense discomfort routine for this woman, was produced
      in association with Soy Passiflora aiming to control anxiety and hot flushes
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Menopause Rating Scale - MRS</measure>
    <time_frame>104 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kuppperman-Blatt index</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRS scale</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MENQOL</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Climacteric Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients enrolled in this arm will take a tablet twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Passiflora incarnata and isoflavona combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients enrolled in this arm will take a tablet twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active drug</intervention_name>
    <arm_group_label>Passiflora incarnata and isoflavona combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female amenorrheic for at least one (1) year or surgical menopause since dosage of
             FSH ≥ 30 mIU / ml;

          -  Age greater than or equal to 40 and less than or equal to 65 years;

          -  Cytological examination colpo held at screening visit, Pap cytology classification
             with class I and II;

          -  By mammography BI-RADS classification (fourth edition) rated one (1) or two (2)
             performed at least six (6) months from the time of inclusion in the screening visit
             or if the research subject does not present a recent survey ;

          -  Line endometrial ≤ 8 mm by transvaginal ultrasound, performed at screening visit, in
             the case of subjects who have an intact uterus;

        Exclusion Criteria:

          -  History of severe liver or renal disease at the discretion of the investigator;

          -  Hypertension stage III uncontrolled (SBP ≥ 180 mmHg or DBP ≥ 110 mmHg);

          -  Important cardiovascular disease such as coronary insufficiency or dilated
             cardiomyopathy advanced;

          -  Using estrogens, progestins, steroid or hormone replacement therapy (HRT) in the last
             3 months;

          -  Estrogen-dependent neoplasia;

          -  Thromboembolic disorders for less than one year of screening visit;

          -  Anabolic drugs use or illicit drug use;

          -  Hemoglobin &lt; 10 or &gt; 17 g / dL;

          -  TSH &lt; 0, 550 or &gt; 4, 780 UUI / L;

          -  FT4 &lt; 0.75 ηg / dL or &gt; 1.8 ηg / dL;

          -  Patient that is chronically using MAO inhibitors (MAOIs) or levothyroxine
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Monica Mathias, Doctor</last_name>
    <phone>+55 11 99996 6482</phone>
    <email>monica.mathias@ache.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>ISBEM</name>
      <address>
        <city>São Paulo</city>
        <zip>04062-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>César Eduardo Fernandes, Doctor</last_name>
      <phone>+55 11 5583 1511</phone>
      <email>pesquisa@isbem.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Eloisiei Garbugio</last_name>
      <phone>+55 11 5583 1511</phone>
      <email>elo@isbem.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>César Fernandes, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Regina Ares, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonia Yurico Omori Del Debbio, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renata Alexandra Calixto Pinheiro, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 27, 2012</lastchanged_date>
  <firstreceived_date>September 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
